Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||FT516 + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FT516||FT-516|iPSC-derived CD16-expressing Natural Killer Cells FT516||FT516 are iPSC-derived allogeneic NK cells engineered to express hnCD16, which may stimulate anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 3191).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 10||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lymphoma||not applicable||FT516 + Rituximab||Preclinical - Cell line xenograft||Actionable||In a preclinical study, FT516 in combination with Rituxan (rituximab) enhanced ADCC and cytokine production, resulted in reduced tumor burden in cell line xenograft models of disseminated lymphoma (Cancer Res 2019;79(13 Suppl):Abstract nr 3191).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|